ORG Partners’s Enliven Therapeutics ELVN Stock Holding History

ORG Partners’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-225	Closed	-$4.61K	–	1727
2025 Q3	$4.61K	Buy	+225	New	+$4.54K	﹤0.01%	1151

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ORG Partners's ELVN Position: Q4 2025 in Review

ORG Partners sold out of Enliven Therapeutics (ELVN) in Q4 2025, closing a stake of 225 shares — an estimated $4.61K sold.

ORG Partners first reported a position in ELVN in Q3 2025 and held it in 1 quarter. The position peaked at $4.61K in Q3 2025. 125 funds tracked by Wall St. Rank hold ELVN as of Q4 2025.

ORG Partners reported no remaining Enliven Therapeutics position as of Q4 2025 after selling out during the quarter.
ORG Partners sold 225 Enliven Therapeutics shares in Q4 2025, an estimated $4.61K.
ORG Partners first reported a position in Enliven Therapeutics in Q3 2025 and held it in 1 quarter.
ORG Partners's Enliven Therapeutics position peaked at $4.61K in Q3 2025.
125 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.